We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+19.58%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$161M
AUM Growth
+$20.9M
Cap. Flow
-$8.51M
Cap. Flow %
-5.29%
Top 10 Hldgs %
48.45%
Holding
88
New
12
Increased
11
Reduced
19
Closed
14

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$4.07M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.08M
3
CBAY
Cymabay Therapeutics
CBAY
+$2.81M
4
ACHN
Achillion Pharmaceuticals
ACHN
+$2.01M
5
TVRD
Tvardi Therapeutics
TVRD
+$1.31M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$3.22M
2
SPNC
Spectranetics Corp
SPNC
+$2.15M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.98M
4
CLLS
Cellectis
CLLS
+$1.97M
5
IMMU
Immunomedics Inc
IMMU
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 80.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
26
DELISTED
Cidara Therapeutics
CDTX
$1.69M 1.05%
10,423
– –
QURE icon
27
uniQure
QURE
$2.63B
$1.68M 1.05%
175,307
-28,600
-14% -$230K
AGTC
28
DELISTED
Applied Genetic Technologies Corporation
AGTC
$1.66M 1.03%
421,000
– –
BEAT
29
DELISTED
BioTelemetry, Inc.
BEAT
$1.65M 1.02%
50,000
-25,000
-33% -$866K
VIRX
30
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.61M 1%
23,752
-543
-2% -$44.3K
KURA icon
31
Kura Oncology
KURA
$901M
$1.58M 0.98%
+105,859
New +$994K
NDRM
32
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.48M 0.92%
37,938
– –
FOMX
33
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.44M 0.89%
258,667
-97,000
-27% -$501K
NERV icon
34
Minerva Neurosciences
NERV
$196M
$1.3M 0.81%
21,387
-13,153
-38% -$754K
TVRD
35
Tvardi Therapeutics
TVRD
$23.8M
$1.28M 0.8%
+2,606
New +$1.31M
JNJ icon
36
Johnson & Johnson
JNJ
$641B
$1.22M 0.76%
9,400
– –
SCYX icon
37
SCYNEXIS
SCYX
$35.5M
$1.22M 0.76%
6,336
– –
NGNE icon
38
Neurogene
NGNE
$691M
$1.13M 0.7%
+3,977
New +$1.14M
RIGL icon
39
Rigel Pharmaceuticals
RIGL
$692M
$1.13M 0.7%
44,348
– –
STXS icon
40
Stereotaxis
STXS
$130M
$1.13M 0.7%
1,372,862
– –
XENE icon
41
Xenon Pharmaceuticals
XENE
$6.36B
$1.11M 0.69%
377,695
– –
ADXS
42
DELISTED
Advaxis Inc
ADXS
$1.03M 0.64%
16,467
– –
CMTA
43
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$1.01M 0.63%
+60,000
New +$981K
EXAC
44
DELISTED
Exactech Inc
EXAC
$907K 0.56%
27,532
+4,396
+19% +$132K
ARGX icon
45
argenx
ARGX
$55.6B
$904K 0.56%
40,000
– –
CGNT
46
DELISTED
Cogentix Medical, Inc.
CGNT
$828K 0.51%
323,482
-30,000
-8% -$65.7K
OBSV
47
DELISTED
ObsEva SA Ordinary Shares
OBSV
$700K 0.43%
86,000
+61,000
+244% +$464K
BLUE
48
DELISTED
bluebird bio
BLUE
$618K 0.38%
347
-271
-44% -$379K
LMNX
49
DELISTED
Luminex Corp
LMNX
$508K 0.32%
+25,000
New +$498K
CASC
50
DELISTED
Cascadian Therapeutics, Inc.
CASC
$480K 0.3%
117,310
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, DAFNA Capital Management held 88 positions worth $161M, up 15% from $140M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management withdrew a net $8.51M in Q3 2017, closing 14 positions and reducing 19 holdings. Its most notable exit was Spectranetics Corp, an estimated $2.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 80% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in DexCom worth $2.81M.

  • DAFNA Capital Management's largest Q3 2017 buy was DexCom: 230,000 shares worth $2.81M.
  • DAFNA Capital Management added most to BioCryst Pharmaceuticals in Q3 2017, an estimated $3.08M increase.
  • DAFNA Capital Management's biggest Q3 2017 reduction was Loxo Oncology, Inc, cutting an estimated $3.22M.
  • DAFNA Capital Management fully exited Spectranetics Corp in Q3 2017, selling an estimated $2.15M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $161M portfolio in Q3 2017.
  • DAFNA Capital Management opened 12 new positions and closed 14 in Q3 2017.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $161M.

Based on DAFNA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.